Estimated Control Closed Transaction verified Blister CareConsumerConsumer Self CareConsumer Self Care / Nonprescription HealthcareNonprescription HealthcareOTC Self Care

Héra / HRA Pharma acquired by Perrigo

Perrigo acquired Héra / HRA Pharma, an otc self care / consumer healthcare brand on Sep 8, 2021. The transaction value is shown as USD 2.1bn. The current comp implies EV / revenue of 4.45x.

Transaction summary

Target: Héra / HRA Pharma
Acquirer: Perrigo
Seller: Astorg and Goldman Sachs Asset Management
Announced: 2021-09-08
Geography: -
Tags: Blister CareConsumerConsumer Self CareConsumer Self Care / Nonprescription HealthcareNonprescription HealthcareOTC Self CareOTC Self Care / Consumer HealthcareScar CareSkincareWomen'S Health
Type: Acquisition
Deal type: Control
Stake acquired: -
First added: 2026-06-18
Latest update: 2026-07-13

Value and multiples

Price / value

USD 2.1B

Transaction value | USD

Basis: Public source

EV / revenue

4.45x

Period: Forward 2023

Basis: Derived from source data

EV / EBITDA

EBITDA basis not stated

Basis: Derived from source data

Basis

USD 2.1bn transaction value is treated as publicly disclosed or derived directly from public source data.
Implied EV / revenue is 4.45x, calculated from USD 2.1bn value and USD 472m revenue.
Revenue and multiple inputs are not fully disclosed in public transaction materials reviewed; treat the multiple as an estimate.
Metric period: Forward 2023.

Other reviewed estimates

Transaction comps can involve reported or estimated figures from different sources. FundComb uses the values above as the current canonical comp, while preserving prior reviewed estimates below for context.

EBITDA of 117 and 18.0x EBITDA multiple come from pasted spreadsheet context only; public web evidence supplied verifies the transaction and headline value but not EBITDA or multiple.

EBITDA USD 117m | EV / EBITDA 18x

EV/Sales 4.8x and EBITDA multiple 18.0x are from pasted spreadsheet context, not verified by supplied public web evidence.

EV / revenue 4.8x | EV / EBITDA 18x

Source summary

Perrigo dishes out $2.1B for HRA Pharma, a big step on its quest to become a self-care company

Estimated

Article states Perrigo agreed to acquire HRA Pharma for $2.1 billion and that Perrigo expected the transaction to deliver about €400 million, roughly $472 million, in sales by 2023.

Open source